[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Center for Clinical and Cosmetic Research\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":79},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100596133","evaluating-the-combined-use-of-supplement-and-serum-in-promoting-hair-growth-in-women-with-self-perceived-thinning-hair-100596133",false,"NCT07041489","Evaluating the Combined Use of Supplement and Serum in Promoting Hair Growth in Women With Self-perceived Thinning Hair","A Multi Center, Randomized, Double-Blind, Placebo-controlled Trial With Extension to an Open-Label Study to Evaluate the Safety and Efficacy of Xtressé™ Supplement + Serum Treatment Combination in Promoting Hair Growth in Women With Self-perceived Thinning Hair","Inclusion Criteria:\n\n* Female adults between 28-65 years of age with consistent self-perceived thinning hair.\n* Ludwig Scale I or II (mild to moderate thinning hair loss), assessed clinically.\n* Fitzpatrick Skin Types I to VI.\n* Agree to maintain their current diet, medications, exercise routines, hair shampooing, and color treatment frequency for the duration of the study.\n* Ability and willingness to comply with the study protocol including regular visits and product application.\n* Written informed consent obtained, including written consent to allow photographs to be used as part of the study data and documentation.\n* For females of childbearing potential, a negative pregnancy test at screening and commitment to effective contraception throughout the study (oral \u002F implant\u002F injectable\u002F transdermal contraceptives, intrauterine device, condom, diaphragm, abstinence, or a monogamous relationship with a partner who has had a vasectomy) to avoid pregnancy-related hormonal changes affecting hair density.\n\nExclusion Criteria:\n\n* Pregnant or lactating or planning to become pregnant.\n* Changes in hormonal therapy within 6 months prior to enrollment and throughout the study.\n* Use of other medical hair loss treatments (e.g., Minoxidil, Dutasteride, Finasteride, laser or light therapy) within 3 months prior to study start and throughout the study.\n* Micro-needling, PRP, or any other physical treatment modality on the scalp (within 6 months prior to study start and throughout the study).\n* Use of GLP-1 inhibitors (e.g., Semaglutide) within 6 months prior to study start and throughout the study.\n* Known uncontrolled health conditions (e.g., thyroid disease, anemia) that could confound study outcomes.\n* Known sensitivity to any of the ingredients in the study medication.\n* In the investigator's opinion, evidence of unwillingness, or inability to follow the restrictions and requirements of the protocol and complete the study.\n* Subject has any conditions, findings in history, physical exam or laboratory assessments, which in the opinion of the investigator, would exclude the subject from continuing in this study.\n* Treatment with an experimental drug, biologic or device within 12 weeks of the screening visit.",true,"FEMALE","28 Years","65 Years",{"count":21,"type":22},85,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to test how safe and effective it is to improve hair growth using an active gummy and serum combination treatment when compared to an inactive treatment combination in women with self-perceived thinning hair.\n\nThe main questions this trial aims to answer are:\n\n* to confirm using photograph analytics, how much hair growth has increased in a marked area when using active treatment versus inactive treatment, and\n* participants assessment and satisfaction with the hair growth using scaled assessments.\n\nParticipants who qualify will be asked to complete 6 to 7 visits after voluntarily consent has been given. The study is divided into two parts. In Part A participants will be randomly given either active or inactive treatment to use over 3 months. After 3 months, all participants will enter Part B of the study and will be given active treatment to use over the final 6 months of the study.",[28],"Hair Thinning",[30,31,32,33],"hair thinning","thinning hair","hair loss","thin hair","RECRUITING","2025-06-18",{"date":37,"type":38},"2025-06-27","ACTUAL",{"date":40,"type":38},"2025-05-20",{"date":42,"type":22},"2026-03-30",{"name":44,"class":45},"The Center for Clinical and Cosmetic Research","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100560451","phase-2-evaluating-the-use-of-photodynamic-therapy-to-treat-facial-cutaneous-squamous-cell-carcinoma-in-situ-sccis-100560451","NCT06577311","Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis)","An Investigator Initiated Study to Evaluate the Safety and Efficacy of Aminolevulinic Acid Hydrochloride Topical Gel, 10% (Ameluz ®) With RhodoLED-XL® Red Light in the Treatment of Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis)\"","Inclusion Criteria:\n\n* Must be an adult (18 years of age or older)\n* Must have a recently diagnosed (no more than six months from first study visit) facial SCCis lesion that meets surgery excision size requirements\n* Cannot have other dermatological disease in the SCCis target area\n* Must be willing to follow study instructions and complete study requirements, including not using non-approved lotions and creams on the treatments areas\n* Voluntary written consent required\n* Allow photographs of the area of skin cancer being treated on the face\n* Agree to use acceptable forms of birth control. If female, cannot be pregnant before and during the study\n\nExclusion Criteria:\n\n* Pregnant or lactating\n* Sensitive to any of the study treatment ingredients\n* Medical laboratory evidence of other non-SCCis tumor in the target lesion biopsy specimen\n* History of recurrence if the target SCCis lesion\n* Evidence of dermatological disease or skin condition in the treatment area\n* Medical laboratory evidence of growth patterns in the target lesion biopsy specimen\n* Chronic medical condition that in the Investigators opinion will interfere in the trial or affect participant safety.","ALL","18 Years",{"count":56,"type":22},20,[58],"PHASE2","The goal of this clinical trial is to test how safe and effective it is to treat early form of cancer cells found in the upper skin layer of the face, using a light-sensitive gel used in combination with a light source.\n\nThe main questions this trial aims to answer are:\n\n* to confirm using laboratory testing, how much of the affected facial skin cancer section the treatment was able to remove, and;\n* seeing how many participants had no remaining affected facial skin cancer sections after treatment.\n\nParticipants who qualify will be asked to complete 14 visits in total and will receive a total of two treatments, after voluntarily consent has been given.",[61],"Cutaneous Squamous Cell Carcinoma",[63,64,65,66,67,68,69],"skin cancer","facial skin cancer","Squamous Cell Carcinoma","Squamous Cell Carcinoma in Situ","Cutaneous Squamous Cell Carcinoma in Situ","Facial Cutaneous Squamous Cell Carcinoma in Situ","SCCis","2024-08-27",{"date":72,"type":38},"2024-08-29",{"date":74,"type":38},"2024-08-14",{"date":76,"type":22},"2025-08",{"name":44,"class":45},1,""]